CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionReturn on assets is -90.4%, lower than 95% of its Biotechnology peers (median -20.1%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
310.93MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.24xvs all stocks
52-Week Change
-11.54%vs all stocks
Market Capitalization
310.93MUSDvs all stocks (USD)
Enterprise Value
329.12MUSDvs all stocks (USD)
Forward P/E
-1.26xvs Biotechnology peers
Enterprise to EBITDA
-14.23xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-90.35%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 27, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-23.13MUSDvs all stocks (USD)
Net Income (TTM)
-44.18MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-17.25MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-772.00KUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · May 31, 2025Operating Income
9.66MUSDvs all stocks (USD)
Pre-tax Income
3.75MUSDFY2025 · May 31, 2025Income Tax Expense
0.00USDFY2025 · May 31, 2025Net Income
3.75MUSDFY2025 · May 31, 2025EBIT
8.58MUSDFY2025 · May 31, 2025EBITDA (Income Statement)
9.04MUSDFY2025 · May 31, 2025Research & Development
-16.92MUSDFY2025 · May 31, 2025Selling, General & Administrative
7.26MUSDFY2025 · May 31, 2025Non-operating Interest Income
565.00KUSDFY2025 · May 31, 2025Non-operating Interest Expense
4.83MUSDFY2025 · May 31, 2025EPS (Basic)
0.00USDFY2025 · May 31, 2025EPS (Diluted)
0.00USDFY2025 · May 31, 2025Basic Shares Outstanding
1.21BSharesFY2025 · May 31, 2025Diluted Shares Outstanding
1.21BSharesFY2025 · May 31, 2025Net Income from Continuing Operations
3.75MUSDFY2025 · May 31, 2025Operating Cash Flow
5.38MUSDFY2025 · May 31, 2025Cash & Cash Equivalents (End of Period)
11.90MUSDFY2025 · May 31, 2025Interest Paid
25.00KUSDFY2025 · May 31, 2025Starting Profit (CF Statement)
3.75MUSDFY2025 · May 31, 2025Depreciation & Amortization
18.00KUSDFY2025 · May 31, 2025Stock-based Compensation
1.61MUSDFY2025 · May 31, 2025Long-term Debt Payments
-710.00KUSDFY2025 · May 31, 2025Net Short-term Debt Issuance
-710.00KUSDFY2025 · May 31, 2025Net Financing Cash Flow
-1.42MUSDFY2025 · May 31, 2025Shares Outstanding
1.37BSharesUpdated Sep 27, 2026Float Shares
1.38BSharesUpdated Sep 27, 2026% Held by Insiders
0.01%vs all stocks
% Held by Institutions
0.01%vs all stocks
Total Cash (MRQ)
11.85MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.0090USDUpdated Sep 27, 2026Total Debt (MRQ)
27.28MUSDvs all stocks (USD)
Current Ratio (MRQ)
0.2580xvs Biotechnology peers
Book Value per Share (MRQ)
-0.0800USDUpdated Sep 27, 2026Total Assets
18.05MUSDvs all stocks (USD)
Total Current Assets
17.88MUSDFY2025 · May 31, 2025Total Liabilities
114.09MUSDFY2025 · May 31, 2025Total Non-current Assets
169.00KUSDFY2025 · May 31, 2025Total Non-current Liabilities
43.57MUSDFY2025 · May 31, 2025Total Current Liabilities
70.52MUSDFY2025 · May 31, 2025Cash
11.90MUSDFY2025 · May 31, 2025Cash & Cash Equivalents
11.90MUSDFY2025 · May 31, 2025Accounts Payable
14.69MUSDFY2025 · May 31, 2025Short-term Debt
27.34MUSDFY2025 · May 31, 2025Other Current Liabilities
145.00KUSDFY2025 · May 31, 2025Long-term Debt
0.00USDFY2025 · May 31, 2025Other Non-current Liabilities
43.57MUSDFY2025 · May 31, 2025Common Stock (Book)
1.25MUSDFY2025 · May 31, 2025Retained Earnings
-887.79MUSDFY2025 · May 31, 2025Total Shareholders' Equity
-96.04MUSDvs all stocks (USD)
Treasury Stock
0.00USDFY2025 · May 31, 202552-Week Low
0.1800USDUpdated Sep 27, 202652-Week High
0.4000USDUpdated Sep 27, 202652-Week Change
-11.54%vs all stocks
Beta
1.24xvs all stocks
50-Day MA
0.2050USDUpdated Sep 27, 2026200-Day MA
0.2615USDUpdated Sep 27, 2026Avg 10-Day Volume
998.53KSharesUpdated Sep 27, 2026Avg 30-Day Volume
1.39MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-0.0300USDUpdated Sep 27, 2026Other Income / Expense
-445.00KUSDFY2025 · May 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on assets is -90.4%, lower than 95% of its Biotechnology peers (median -20.1%)Significant
Return on assets: -0.90Industry median: -0.20Industry P5: -0.83Peers compared: 260
Current ratio is 0.26×, lower than 95% of its Biotechnology peers (median 5.71×)Significant
Current ratio: 0.26Industry median: 5.71Industry P5: 1.02Peers compared: 260
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Guiyang Xintian Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aprilbio Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Vanda Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Won Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Animalcare Group Plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Abeona Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jilin Province Xidian Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Evommune, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
AtaiBeckley Inc.
Tier 1ProductionApproval-Gated PipelineRule
Medy-Tox Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Qingdao Eastsoft Communication Co., Ltd.
1 interpretationPartial Recovery After Sharp Decline
Sunwoda Electronic Co., Ltd.
1 interpretationPartial Recovery After Sharp Decline
Xianheng International Science And Technology Co., Ltd.
1 interpretationPartial Recovery After Sharp Decline